Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage

Profound Medical Corp.

2026-Q1 EPS reported $0.19 revenue$5,337,000

Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.
Net loss improved 34% to $7.0M ($0.19 per share) from $10.7M in Q1 2025.
Humana became first national U.S. payor to cover the TULSA Procedure, adding ~8.5M covered lives.
CAPTAIN trial met primary safety endpoint; TULSA INDEX20 average procedures per quarter rose to 11.3.
Full-year 2026 revenue guidance set at ~$25M, representing 56% growth over prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Profound Medical Corp. reported the first quarter ended March 31, 2026 results: revenue $5.3 million, net income $7.0 million, EPS $0.19 per common share. Guidance initiated.

Period: the first quarter ended March 31, 2026
Revenue: $5.3 million
Net income: $7.0 million
EPS: $0.19 per common share
Guidance: initiated
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2026, Profound recorded revenue of approximately $5.3 million

View on SEC.gov

Browse all earnings releases →

Profound Medical Corp. filing history →

Source: SEC EDGAR

accession 0001171843-26-003160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.